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Abstract
Background: Interleukin-1 receptor antagonist, a cytokine that is highly therapeutic to rheumatoid arthritis and
several other inflammatory diseases, exhibits rapid blood clearance and poor retention time on the target in clinical
application due to its small size and lack of specificity to target tissue. Albumin has been widely employed as
macromolecular carrier for drug delivery purpose to extend the plasma half-life of therapeutic molecules and has
been shown to selectively accumulate and to be metabolized in the inflamed joints of patients with rheumatoid
arthritis. This suggests that genetic fusion of IL-1ra to albumin can probably overcome the drawbacks of in vivo
application of IL-1ra.
Result: A recombinant protein, engineered by fusing human serum albumin (HSA) to the carboxyl terminal of
IL-1ra, was produced in Pichia pastoris and purified to homogeneity. The fusion protein retained the antagonist
activity of IL-1ra and had a plasma half-life of approximately 30-fold more than that of IL-1ra in healthy mice. In vivo
bio-distribution studies demonstrated that the fusion protein selectively accumulated in arthritic paws for a long
period of time in mice with collagen-induced arthritis, showing low uptake rates in normal organs such as liver,
kidney, spleen and lung in contrast to IL-1ra alone. Moreover, this fusion protein was able to significantly improve
the therapeutic efficacy of IL-1ra in collagen-induced arthritis mouse model.
Conclusions: The fusion protein described here, able to selectively deliver IL-1ra to inflamed tissue, could yield
important contributions for the therapy of rheumatoid arthritis and other inflammatory diseases.
Keywords: Human serum albumin, Interleukin-1 receptor antagonist, Fusion protein, Rheumatoid arthritis,
Pharmacokinetics, Pharmacodynamic
Background
Rheumatoid arthritis (RA) is a chronic inflammatory dis-
order characterized by systemic autoimmune attacking
synovial joints, leading to articular destruction and func-
tional disability and a wide array of extra-articular com-
plications [1]. There is increasing evidence that
Interleukin-1 (IL-1) plays an important role in several
chronic inflammatory diseases, including RA [2]. The
IL-1β-NF-κB axis is a key pathway in the pathogenesis
of RA. NF-κB activation by IL-1β induces a widely
spectrum of pro-inflammatory mediators that contribute
to the inflammation in the synovium [2]. IL-1 also acti-
vates the fibroblast-like synoviocytes through the IL-1β-
NF-κB pathway to produce a family of MMPs, resulting
in collagen degradation and bone erosion [3,4]. There-
fore, blocking the effect of an excess of IL-1 may provide
a therapeutic option of RA. Interleukin-1 receptor antag-
onist (IL-1ra), a member of IL-1 family, is a naturally oc-
curring cytokine that blocks biological activity of IL-1
through binding to IL-1 type I receptor with the same
affinity as that of IL-1β. Recombinant human IL-1ra
(rhIL-1ra), Anakinra, has been approved for the treat-
ment of patients with moderate-severe rheumatoid arth-
ritis (RA) and has been shown to slow cartilage
degradation and to provide relief from joint symptoms
when administered subcutaneously [5-7]. rhIL-1ra is also
documented to have therapeutic potential for several
other autoimmunity diseases associated with IL-1 dysre-
gulation [8]. However, IL-1ra exhibits rapid blood clear-
ance and poor retention time on the target in clinical
application, due to its small size and lack of specificity
to the target tissue [9]. High dosages and repeated
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injections are therefore required, which greatly influ-
ences patients' physical, psychological and economical
situation. Additionally, systemic administration of a
high dosage (150 mg/day) usually exposes patients to
complications that include injection site reactions, ser-
ious bacterial infection, high risk of tumorigenesis, and
neutropenia [6,10-14]. The pharmacokinetic properties
of small protein drugs can probably be improved by co-
valent coupling to a suitable carrier, which should be
characterized by such features as long circulation half-
life, high accumulation in the target tissue, and low up-
take rates in normal tissue, as well as low toxicity and
general availability. The plasma protein albumin satisfies
these requirements for drug delivery as demonstrated by
a number of studies.
Albumin is the most abundant plasma protein with a
molecular weight of 66.5 kDa. It is produced as a mono-
meric protein in the liver and has an average circulation
half-life of 19 days in humans. This long serum half-life
is due to a recycling process mediated by the neonatal
Fc receptor (FcRn), similar to that observed for IgG
molecules [15,16]. Albumin has a simple molecular
structure and is highly stable. In addition to its role in
regulating the osmotic pressure of plasma, albumin
serves as a carrier for the transport of metabolites like
long chain fatty acids, bilirubin, steroid hormones, tryp-
tophan, and calcium. Albumin also binds with high af-
finity to a broad range of drugs influencing their
pharmacokinetic properties [17]. Taking these advan-
tages into consideration, albumin has been employed as
macromolecular carrier for drug delivery purpose to im-
prove pharmacokinetic properties and efficacy of thera-
peutic molecules [18-21]. In addition, albumin has been
shown to selectively accumulate in the inflamed joints of
RA patients and of mice suffering from collagen-induced
arthritis [22-26], indicating it is an attractive carrier for
targeted delivery of drugs to the inflamed sites. The anti-
rheumatic conpound methotrexate covalently linked to
albumin has shown promising activity in the collagen-
induced arthritis model [26]. Non-covalently binding
protein drugs to albumin by fusing these drugs to anti-
albumin antibody fragments also results in prolonged
half-lives and selective accumulation of the drugs in
inflamed joints [27,28]. However, it has not been docu-
mented so far whether direct fusion of protein drugs to
albumin has the same effect as mentioned above.
Herein, we report the engineering and production of a
fusion protein that consists of human IL-1ra and HSA
and its application prospect for RA therapy. We demon-
strated that the fusion protein retained the bioactivities
of IL-1ra and had a much longer serum half-life than IL-
1ra in mice. The fusion protein also selectively accumu-
lated in arthritic joints of mice for a long period of time,
with low distribution rates in other organs such as liver,
kidney, spleen and lung, in contrast to IL-1ra alone. In
addition, the fusion protein exhibited a more pro-
nounced therapeutic efficacy in mice arthritis model
compared with IL-1ra. The findings reported herein in-
dicate that the fusion protein is likely to be an ideal bio-
logical agent in the treatment of rheumatoid arthritis,
and that genetic fusion of small protein drugs to albu-
min is a promising drug delivery approach for RA tar-
geted therapy.
Results
Engineering and identification of fusion protein
The fusion gene, inserted into the plasmid vector
pHBM905B, was confirmed by DNA sequencing, and
the positive transformants (P. pastoris GS115 (his4))
were identified by specific amplification of the fusion
gene (PCR) using genomic DNA as templates. The
results demonstrated that the target fragment of the vec-
tor pHBM905B/IL-1ra-HSA was integrated into the gen-
ome of P. pastoris GS115 (his4). The fusion gene was
inserted into the downstream of α-factor signal peptide
within the same frame and under the control of AOX1
(Alochol Oxidase) promoter, allowing the fusion protein
to be expressed and successfully secreted into the cul-
ture medium. The fusion protein was expressed as a
91 kDa functional protein in the culture medium and
the expression level was positively correlated with the
induction time. The highest expression level was
achieved after 120 h of induction, which accounted for
approx. 60% of the total protein in the medium. The tar-
get protein was further identified by immunoblotting.
After ammonium sulfate precipitation, the fusion protein
was routinely purified to greater than 90% purity using
IMAC (Figure 1). We routinely obtained 18–20 mg of
Figure 1 Purification and gel filtration analysis of the fusion
protein. (A) SDS/PAGE under reducing condition shows the result
of purification. Lane M, the molecular mass standards(kDa); lane 1,
the fusion protein. The molecular masses in kDa are given on the
right of the gel. (B) Gel filtration analysis of the fusion protein on a
TSK-G3000-SWXL column. The molecular mass standards are IgG
(150 kDa) and BSA (66 kDa).
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fusion protein from a 1 liter medium supernatant. On
concentration by ultrafiltration, a concentration of at least
1 mg/ml for fusion protein could be obtained. The puri-
fied protein was further checked by gel filtration chroma-
tography. The fusion protein was eluted at a retention
time of 11.9 min, which corresponded to a molecular mass
of about 91 kDa consistent with a monomer (Figure 1).
No polymer peaks and other protein peaks were observed,
which indicated that the fusion protein was homogeneous
in the form of monomer with a high purity.
In vitro bioactivity of fusion protein
IL-1ra is a natural antagonist that blocks IL-1 action by
competitively binding to the IL-1 receptors, thus pre-
venting the biological response mediated by IL-1. Im-
munofluorescence analysis revealed a dose-dependent
binding of fusion protein to IL-1 receptor positive A375.
S2 cells. As expected, IL-1ra also bound to A375.S2 cells
in a dose-dependent manner, whereas no binding of
HSA to A375.S2 cells was observed (Figure 2). The
experiments clearly demonstrate that the receptor bind-
ing ability of IL-1ra is not impaired by fusion to HSA.
IL-1 is cytotoxic to A375.S2 cell through IL-1 receptor-
mediated signal pathway, and the cytolytic activity of IL-
1 can be blocked by IL-1ra. Therefore, the fusion protein
was also examined for its capacity to inhibit IL-1-
dependent A375.S2 cells killing. As shown in Figure 3,
both IL-1ra and fusion protein inhibited the cytolytic ac-
tivity of 1 ng/ml (0.06 nM) of IL-1β to A375.S2 cells in a
dose-dependent manner. For the fusion protein, the 50%
and the 100% level of inhibition were achieved at an in-
put of approx. 2 nM and 32 nM respectively, showing a
slight reduction of activity compared with IL-1ra. By
contrast, HSA did not show any inhibitory effect. These
results indicate that fusion protein retains IL-1 antagon-
ist activity, similar to that of IL-1ra.
Serum albumin levels in arthritic mice and healthy
control mice
The serum albumin level in arthritic mice was 23.1 ±
3.1 g/L, which was significant lower than that in healthy
mice (35.7 ± 3.8 g/L). On the contrary, the albumin level
(1.07 ± 0.18 mg/g) in the inflamed joints of arthritic
mice was about 6-fold more than that (0.18 ± 0.07 mg/
g) in the joints of healthy mice. The results suggest that
mice with CIA can also develop to hypoalbuminemia, a
serious complication due to accelerated metabolism of
albumin in inflamed joints as demonstrated by a number
of studies in RA patients [22-25]. This is the theoretical
basis of our albumin-based targeted therapy.
Pharmacokinetics analysis of fusion protein
The amounts of radiaolabeled fusion protein and radi-
olabeled IL-1ra present in blood circulation in the
healthy mice at different time points are shown in
Figure 4. At 10 min post-injection, about 90% of the fu-
sion protein tracer could be found in the circulation, com-
pare with 65% of IL-1ra tracer. The circulation tracer of
IL-1ra decreased to about 40% after 30 min, and was com-
pletely cleared from the circulation after 8 h. By compari-
son, the fusion protein decreased at a much lower rate
than the levels of IL-1ra, with the circulation tracer of
approx. 85% after 30 min and approx.55% after 8 h. At
48 h post-injection, approx.30% of the fusion protein
could be still observed in the circulation. Generally, it
would take 120 hours for the fusion protein to be com-
pletely cleared from the circulation. The data indicate that
the fusion protein has a longer retention time in blood cir-
culation compared with IL-1ra. Analysis of the obtained
curves by the GraphPad software yielded the half-life
of the fusion protein was 9.8 ± 1.7 h, compared to
0.34 ± 0.05 h for IL-1ra. The plasma levels of fusion
protein in arthritic mice at different time points
Figure 2 Immuno-fluorescence staining detection for the receptor-binding of the fusion protein. A375.S2 cells incubated with 100 μg/ml
fusion protein (1), with 10 μg/ml fusion protein (2), with 1 μg/ml fusion protein (3), with 0.1 μg/ml fusion protein (4), with 0 μg/ml fusion protein
(5), and with 100 μg/ml HSA (6). FITC-labeled anti-His tag mAb is used in this assay. The fusion protein, IL-1ra and HSA have a His tag at the C-
terminal.
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showed no significant difference in comparison with
those in healthy mice, and so did the plasma levels of
IL-1ra (not shown).
Uptake in paws and biodistribution of fusion protein
On the 11th day after the second immunization, all the
mice showed the first sign of disease, predominantly in
the hind paws and hind ankles. The disease was progres-
sive and achieved a clinical score of 12 to 16 in most of
mice 30 days after the second immunization. On this
day, the arthritic mice and healthy mice were assigned
for the biodistribution analysis. The uptake of radiola-
beled fusion protein and radiolabeled IL-1ra by healthy
and inflamed hind paws is illustrated in Figure 5. The
maximal accumulation of fusion protein in arthritic
paws was achieved 13 h after injection. On average, an
individual inflamed hind paw accumulated 4.2 ± 0.3% of
the initial injected radioactivity after 13 h. This value
exceeded that of healthy hind paw by approx. 6-fold.
After 48 h, 3.6 ± 0.3% of the fusion protein was detect-
able in the inflamed hind paws, which was about 15-fold
greater than that remaining in healthy hind paws. The
autoradiograms showed the similar result. After 48 h, a
selectively accumulation of radiolabeled fusion protein
in the inflamed hind paws was observed, whereas accu-
mulation of the fusion protein in healthy hind paws was
not detectable (Figure 5). In contrast to the fusion pro-
tein, radiolabeled IL-1ra showed no accumulation in
inflamed hind paws. Rapid elimination of radiolabeled
IL-1ra was found in hind paws affected by arthritis. The
maximal uptake rate of radiolabeled IL-1ra was obtained
3 h post-injection with the value of 1.8 ± 0.2%, decreas-
ing to 0.8 ± 0.2% after 8 h and to 0.16 ± 0.02% after
48 h, 20-fold less than that of radiolabeled fusion protein
at the same time point. No significant differences were
found between the uptake rates of radiolabeled IL-1ra in
inflamed hind paws and those of radiolabeled IL-1ra in
healthy hind paws. The forepaws showed the similar
results (not shown). The biodistribution of radiolabeled
fusion protein and radiolabeled IL-1ra in liver, kidney,
spleen and lung of arthritic mice and healthy mice at dif-
ferent time points is shown in Figure 6. The maximal
uptake rates of fusion protein in liver, spleen and lung
was achieved 13 h after injection, compared with 3 h for
IL-1ra. The uptake rates of the fusion protein in these
organs of arthritic mice showed no significant differ-
ences compared with those of the fusion protein in the
corresponding organs of healthy mice, and IL-1ra uptake
by these organs showed the similar results. However, the
uptake rates of the fusion protein were significantly
lower than those of IL-1ra in these organs, especially in
the liver and lung, of both arthritic mice and healthy
mice. The organ distribution pattern of the fusion
Figure 3 Dose-dependent inhibition of the cytotoxic effect of IL-1β to A375.S2 cells. (A)% levels of inhibition under varied inputs of the
fusion protein, IL-1ra, and HSA. (B) Inhibition of IL-1β-induced cytotoxicity to A375.S2 cells as shown by photomicroscopy. Cells were incubated in
the presence of 32 nM fusion protein (1), 1 ng/ml (0.06nM) IL-1β alone (2), 0.06nM IL-1β plus 2 nM fusion protein (3), and 0.06nM IL-1β plus 32
nM fusion protein (4). There is no difference: between (1) and cells with medium alone (not shown); between (2) and the cells in 0.06nM IL-1β
plus 32 nM HSA (not shown).
Figure 4 Plasma levels of 131I-labeled fusion protein and131I-
labeled IL-1ra after injection to healthy mice though the tail
vain. Each data point represents mean ± SEM (n = 5). ** = p < 0.01
versus IL-1ra.
Liu et al. BMC Biotechnology 2012, 12:68 Page 4 of 13
http://www.biomedcentral.com/1472-6750/12/68
protein was quite similar to that of HSA, i.e. the highest
concentration was found in blood, followed by lung,
liver, kidney and spleen. In the kidney, the maximal up-
take of IL-1ra appeared 30 min after injection, with the
amount as approx. 6 times as that of the fusion protein.
It is generally thought that IL-1ra was rapidly eliminated
from the blood via glomerular filtration in the kidney.
These results demonstrate that fusion of HSA to IL-1ra
significantly increased its tissue specificity and reduced
its distribution to other organs.
Inhibition of established arthritis in mice
Treatment of mice CIA was carried out on the 11th day
after the second immunization, coinciding with the
Figure 5 (A) Uptake kinetics of 131I-labeled fusion protein and 131I-labeled IL-1ra in hind paws of mice with (n = 5) and without CIA
(n = 5) after intravenous injection. Data are expressed as mean ± SEM. ** = p < 0.01 versus uptake rates of 131I-labeled IL-1ra in hind paws of
arthritic mice or healthy mice and uptake rates of 131I-labeled fusion protein in hind paws of healthy mice. (B) Autoradiogram for the selectively
accumulation of the fusion protein in the inflamed joint of mice. (1) and (2), inflamed paw; (3) and (4), normal paw.
Figure 6 The uptake kinetics of 131I-labeled fusion protein and131I-labeled IL-1ra in the liver (A), kidney (B), spleen (C), and lung (D) of
mice with (n = 5) and without CIA (n = 5). Data are expressed as mean ± SEM. * = p < 0.05 and ** = p < 0.01 versus uptake rates of 131I-
labeled IL-1ra in liver, kidney, spleen, and lung of arthritic mice or healthy mice.
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onset of the disease. The severity of arthritis was moni-
tored by clinical score and paw swelling. Figure 7 shows
the progression of arthritis during the treatment period.
The arthritis score in the saline-treated group increased
slightly and reached a mean value of 12.8 at the end of
the treatment. The same variations were also observed
in the paw swelling of the arthritic mice given saline. In
comparison with the mice treated with saline, a pro-
nounced reduction in clinical score and paw swelling
was observed in mice treated with the fusion protein.
IL-1ra treatment, however, showed a lower suppression
of arthritis progression compared with the fusion pro-
tein. Significant reduction of clinical score and paw swel-
ling only appeared at the end of the treatment. No
significant therapeutic efficacy was found in the HSA-
treated group.
Histopathology
The hind limbs of mice from different groups were
removed for histological analysis of ankle joints. The
histological score given for the saline-treated group was
15.4 ± 2.1 at the end of the experiment. A significant re-
duction in histological score (10.5 ± 1.6) was observed in
the IL-1ra-treated group (p < 0.05). By comparison, the
fusion protein treatment resulted in a histological score
of 3.2 ± 0.6, which is more significant (p < 0.01). As
expected, no significant reduction in histological score
(15.2 ± 2.5) could be found for HSA treatment. Repre-
sentative ankle joint histopathology of the experimental
groups is shown in Figure 8. Arthritis in mice with CIA
is characterized by synovial hyperplasia, pannus forma-
tion, exudation of cells into the joint space, and erosion
of bone and cartilage. A massive influx of inflammatory
cells, synovial hyperplasia, pannus formation, and cartil-
age erosion in the joint space of CIA mice given saline
was obviously observed compared with the normal
control mice. The mice treated with HSA showed the
same pattern of joint damage as that of arthritic mice.
By comparison, mice treated with the fusion protein
revealed pronounced reduction in inflammation and
joint destruction to the extent that the synovial mem-
brane in the joints was almost like the normal synovium,
except for a mild synovial hyperplasia and other charac-
teristics of inflammation. A less degree of arthritis sever-
ity was found in the mice treated with IL-1ra. Despite
no visible damage to the joint, such as bone erosion and
cartilage desquamation, the influx of inflammatory cells
and synovial hyperplasia were somewhat pronounced.
Cytokine expression
To further confirm the anti-arthritis effect of the fusion
protein, the expression of inflammatory cytokines such
as TNF-α, IL-1β, and IL-6 in the joint of mice was ana-
lyzed by a quantitative ELISA at the end of treatment.
As shown in Figure 9, in normal mice, the mean protein
level for TNF-α, IL-1β, and IL-6 was approx. 70, 100,
and 80 pg/g of tissue. A marked increase for the three
cytokines was found in the joints of mice given saline.
Especially for IL-1β, the amount was increased to
approx. 15-fold more than that in the joints of normal
mice. IL-1ra treatment gave a significant reduction in
protein levels of IL-1β and IL-6, whereas no significant
reduction was found for TNF-α. On the other hand, fu-
sion protein treatment resulted in more pronounced re-
duction in the protein levels of the three cytokines. No
downregulation of the three cytokines was observed with
HSA treatment. The results, together with the above
ones, suggest that fusion of HSA to IL-1ra markedly
increases the therapeutic efficacy of IL-1ra to mice CIA,
and that the HSA component of the fusion protein exhi-
bits no therapeutic effect but exerts a synergistic effect
of the fusion on the activity of IL-1ra.
Figure 7 The therapeutic efficacy of proteins in established arthritis in mice. (A) Arthritis scores of CIA mice (n = 5) during 21 days
treatment. (B) Increment in paw swelling of CIA mice (n = 5) during 21 days treatment. Day 1 corresponds to the first day that clinical arthritis
was found. The upward arrows mean the day when the proteins were administrated. Data are expressed as mean ± SEM. * = p < 0.05 and ** = p
< 0.01 versus the clinical score and paw swelling of arthritic mice treatment with saline.
Liu et al. BMC Biotechnology 2012, 12:68 Page 6 of 13
http://www.biomedcentral.com/1472-6750/12/68
Discussion
The present study was carried out to improve the pharma-
cokinetic profiles of IL-1ra, a naturally occurring cytokine
that is highly therapeutic to RA and several other inflam-
matory diseases. Recombinant DNA technology was used
to fuse HSA to IL-1ra in order to enhance the clinical use
of IL-1ra. The fusion protein was successfully expressed in
yeast cells and secreted to the culture medium in func-
tional form. A good yield was obtained followed by a puri-
fication procedure of IMAC, and the fusion protein was
confirmed to be homogeneous in the form of monomer
by gel chromatography analysis. In vitro functional studies
showed that the fusion protein could bind to IL-1 receptor
and inhibit the cytotoxic effect of IL-1β. This suggests that
the antagonist activity of IL-1ra was clearly acquired by
the fusion protein. However, the bioactivity of the fusion
protein showed a slight reduction compared with IL-1ra.
Macromolecularisation has been reported to cause a re-
duction of activity [29]. It is thought that fusion may im-
pose steric hindrance between the substrate and the active
site of the original functional protein. This drawback will
be probably overcome by using different type of linkers
and changing the arrangement of IL-1ra and HSA [29].
Further studies should be focused on how to improve the
bioactivity of the fusion protein.
Two aspects support our concept of albumin-based
targeted drug delivery. On the one hand, the generation
Figure 8 Representative ankle joints histology in mice among the experimental groups (1), normal control; (2) and (3), CIA plus saline;
(4), CIA plus HSA; (5) CIA plus IL-1ra; (6) CIA plus the fusion protein. (a), synovial hyperplasia and exudation of inflammatory cells into the
synovial space; (b), synovial hyperplasia, pannus formation, and erosion of bone and cartilage.
Figure 9 Inflammatory cytokines expression in the joint of
mice among the experimental groups. Data are expressed as
mean ± SEM. * = p < 0.05 and ** = p < 0.01 versus inflammatory
cytokines expression in the joints of arthritic mice treated with saline.
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of albumin fusions has proven to be an effective ap-
proach to improve the plasma half-life of small proteins,
including hormones, cytokines, and antibody fragments
[30-33]. On the other hand, several findings indicate that
high amounts of albumin accumulate and are metabo-
lized in inflamed joints of RA patients. It is well known
that patients with active RA frequently develop a prom-
inent hypoalbuminemia. This is probably due to the
markedly increased permeability of the blood-joint bar-
rier for albumin, leading to high albumin concentration
in synovial fluid and inflammatory edema [22]. Wilkinson
et al. found that hypoalbuminemia in RA was caused
neither by failure of albumin synthesis nor by increased
albumin loss. Increased vessel permeability also could not
be responsible for the formation of hypoalbuminemia, be-
cause extravascular albumin pool of RA patients was
decreased rather than increased. In contrast, albumin ca-
tabolism was significantly increased in RA patients and
was mostly closed to the activity of the disease [23]. The
studies of Ballantyne et al. and Niwa et al. further con-
firmed these results [24,25]. The authors suggested that
the increased turnover of albumin in RA is probably due
to high consumption of albumin at inflammatory sites
where the synovial cells show an active metabolic state
accompanied by a high demand for nitrogen and en-
ergy, and that the increased albumin production can
not compensate the decreased albumin serum level in RA.
The results of our present study are consistent with the
findings outlined above. We could observe a lower level
of albumin in the blood of the arthritic mice com-
pared with healthy mice. Moreover, we could demon-
strate an intensive accumulation of albumin in the
paws affected arthritis.
Although albumin fusion technology has been widely
used to extend the half-lives of hormones, cytokines,
and antibody fragments, very few data are available so
far about its application in targeted delivery of protein
drugs to inflamed joints for RA treatment. It is well
known that protein drugs fused to anti-albumin anti-
bodies showed a dramatically prolonged half-life and se-
lectively accumulated in the inflamed joint [27,28].
However, whether direct fusion of protein drugs to albu-
min has the same effect as described or not still remains
to be further illustrated. This is because the proteins co-
valently linked to albumin may have different metabol-
ism behaviors under in vivo conditions from those non-
covalently bound to albumin. The results of our present
study demonstrate that fusion of protein drugs to albu-
min is also a promising drug delivery approach for the
targeted therapy of RA. After injection of radiolabeled
IL-1ra and radiolabeled fusion protein to mice with or
without CIA, a standard mouse model for RA, we could
observe a marked gain in plasma half-life for the fusion
protein. Moreover, we could demonstrate an intensive
accumulation of the fusion protein in inflamed paws,
but not in healthy paws. In contrast with the fusion pro-
tein, IL-1ra was rapidly removed from the blood circula-
tion and showed no accumulation in inflamed paws. The
distribution assays indicate that the fusion protein is
mainly in the plasma and only a small fraction distri-
butes in the liver, kidney, spleen and lung, similar to the
distribution pattern of HSA. However, IL-1ra shows a
short circulation time and high distribution rates in liver,
kidney, spleen and lung. These data suggest that the un-
favorable pharmacokinetic properties of IL-1ra with re-
gard to plasma half-life and tissue specificity are
substantially improved by albumin fusion. In this study,
the fusion protein shows a serum half-life of bout 10 h,
which is longer than that of the IL-1ra/AlbudAb (a sin-
gle domain anti-albumin antibody fragment) fusion pro-
tein (4.3 h) in mice [27]. This indicates that the
elimination mechanism of proteins covalently bound to
albumin may be different from that of proteins non-
covalently bound to albumin. The long half-life of albu-
min depends on the FcRn-mediated endocytosis and re-
lease pathway, whereas the non-FcRn-binding proteins
are prone to be endocytosed and degraded by cell lyso-
some [15,16]. This suggests that proteins covalently
bound to albumin are probably more resistant to deg-
radation because they always bind to albumin under
in vivo condition. Which one of the two approaches is
more superior is worthy to be studied in the future.
CIA is a polyarthritis induced by sensitization of sus-
ceptible strains of animals with type II collagen. There
are several similarities with the human RA during the
disease initiation and progression, including linkage of
disease to genes residing in the histocompatability locus
[34], mononuclear cell infiltration, pannus development,
fibrin deposition, erosion of cartilage and bone, and
autoreactive T and B cells [35]. Cytokines such as TNF-
α, IL-1β, and IL-6 have been shown to display potent
pro-inflammatory actions that are thought to contribute
to the pathogenesis of RA [36-38]. To complete the pre-
clinical study, we investigated the efficacy of the fusion
protein compared with IL-1ra in mice established CIA.
A comprehensive assessment of clinical symptoms,
histopathology of joints and pro-inflammatory cytokines
was performed to interpret the therapeutic efficacy. Both
the fusion protein and IL-1ra gave a positive effect in all
these parameters. This finding presented here is consist-
ent with the published work which reported the marked
amelioration of established CIA following treatment with
anti-IL-1 mAb or IL-1ra [39-42]. However, IL-1ra treat-
ment showed only a little protection, and often the data
were not significant or at the limit of significance, prob-
ably due to an insufficient dosage and a relatively long
injection interval. This is in accordance with the previ-
ous study that suggested a relatively high dosage and
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sustained infusion of IL-1ra was needed to obtain a sat-
isfactory efficacy [39,40]. In contrast, the fusion protein
showed a much more significant efficacy in suppressing
the CIA progression, with a pronounced reduction in
clinical score, paw swelling, joint damage, and cytokines
expression at the same dosage as that of IL-1ra. This is
undoubtedly due to the extension of plasma half-life and
the specific accumulation of the fusion protein in
inflamed joints.
Conclusions
Taking all the data together, albumin fused IL-1ra
appears to be a suitable drug for the treatment of
patients with RA. With an extended plasma half-life and
selective accumulation in inflamed joints, the fusion pro-
tein promises to substitute daily infusion of high dose of
IL-1ra in RA therapy with once a week dosing or longer.
Additionally, genetic fusion of small protein drug to al-
bumin is a promising approach for targeted therapy of
RA.
Methods
Plasmid, strains and cells
Recombinant plasmid vectors pMD18T/IL-1ra and
pMD18T/HSA were constructed in our laboratory. E.
coli strain Top10 (Tiangen Biotech., Beijing, China) was
used for cloning and maintaining plasmid throughout
the experiments. Pichia pastoris host strain GS115 (his4)
and the integrating plasmid vector pHBM905B were
kindly provided by Professor Lixing Ma(College of Life
Sciences, Hubei University, Wuhan, China) for protein
expression. Human melanoma A375.S2 cells (ATCC)
was stored in our laboratory and when required, cul-
tured in RPMI-1640 medium containing 10% FBS (foetal
bovine serum, Hyclone) at 37°C in a 5% CO2 incubator.
Regents and materials
Recombinant human interleukin-1β (IL-1β) was from
Peprotech (Rocky Hill, NJ, USA). Human IL-1ra and
HSA were cloned and produced in Pichia pastoris in our
laboratory using the same expression vectors and host
cells as described in this study, with 6 histidines (His
tag) in the carboxyl terminal. FITC-labeled anti-His tag
monoclonal antibody (mAb) and HRP-conjugated anti-
His tag mAb were from Santa Cruz Biotechnology
(Santa Cruz, CA, USA).Restriction endonuclease, T4
DNA ligase, DNase, and RNase were from TaKaRa Bio-
technology (Dalian, China). Pfu DNA polymerase was a
product of BioAsia (Shanghai, China). All forward and
reverse primers were purchase from BioAsia (Shanghai,
China). Ni-NTA agarose was from Pharmacia Biotech-
nology Company (Piscataway, NJ, USA). Bovine type II
collagen and Complete Freund’s adjuvant were obtained
from Sigma Chemical Company (StLouis, MO, USA).
The commercial ELISA kit for mouse TNF-α, IL-1β, IL-
6 and albumin were from Biosource international
(Camarillo, CA, USA).
Construction of expression vectors and transformation of
Pichia pastoris cells
The cDNA fragments encoding IL-1ra and HSA were
obtained by PCR using plasmid vector pMD18T/IL-1ra and
pMD18T/HSA as templates, respectively. The primers were
as follow: P1, IL-1ra sense 5’-TTACGGTCCGATGCACA
CAAGAGTGAGGTT-3’; P2, IL-1ra antisense 5’-TGTGCA
TCTGGAGCTGGAGCTGGCTCGTCCTCCTGGAAGTA




Cpo I and a Not I restriction sites were introduced to the
P1 and P4 respectively for cloning purpose. Primers P2
and P3 have a complementary region of 32 base pairs,
containing the sequence encoding a five peptide linker
PAPAP. A 6×histidine (his tag) coding sequence was
introduced into primer P4, insuring that the fusion protein
could be identified by immunoblotting using anti-his tag
antibody and be purified by immobilized Ni2+ affintity
chromatography. The IL-1ra-HSA fusion gene was ampli-
fied by an overlapped PCR using a mixture of the above
two PCR products as templates, with P1 and P4 as pri-
mers. The conditions for the amplification of three gene
fragments were as follows: 95°C for 5 min, followed by
30 cycles of 95°C for 1 min, 55 °C for 1 min, and 72°C for
1 min. The final extension was 72 °C for 5 min. The fusion
gene obtained by the PCR, encoding IL-1ra and HSA
which were linked by a PAPAP peptide linker, was then
digested by CpoI and NotI and ligated into the expression
vector pHBM905B digested by the same enzymes, result-
ing in the recombinant vector pHBM905B/IL-1ra-HSA.
The recombinant vector was transformed into E. coli
Top10 for amplification and DNA sequencing. Recombin-
ant vector pHBM905B/IL-1ra-HSA was linearized by Sal I
and introduced into P. pastoris GS115 (his4) by electro-
poration. Transformants were initially screened for their
viability in the absence of histidine. The positive recombi-
nants were further identified by PCR using primers P1
and P4, and were analyzed with a 0.8% agarose gel.
Expression of fusion protein
The recombinants were inoculated in 25 ml of BMGY
medium (100 mM potassium phosphate buffer, pH6.0,
1% yeast extract, 2% peptone, 4 × 10-5% biotin, 1% v/v
glycerol) and the culture was incubated at 30°C with
constant shaking to reach an A600nm of 6–8. The cells
were then collected by centrifugation at 3,000 g for
10 min and resuspended in 250 ml BMMY medium
(BMGY with 0.5% methanol instead of 1% glycerol) in a
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1-liter shake flask. The cultures were incubated for
120 h at 30°C with constant shaking, and 100% metha-
nol was added to a final concentration of 0.5% every
12 h to maintain induction. The cultures were then cen-
trifuged at 5,000 g for 10 min, and the supernatant was
harvested and checked by 12% SDS/PAGE.
Identification of fusion protein by immunoblotting
Immunoblotting analysis was performed according to
the standard protocol. Briefly, the supernatant was
sampled and separated on a 12% SDS/PAGE and trans-
ferred to a nitrocellulose membrane (Pall Gelman
Sciences, Port Washington, NY, USA; 0.45 μm pore
size). The membrane was blocked in 1 × PBS (pH7.4) so-
lution with 5% nonfat dry milk at 4°C overnight, and
incubated with HRP-conjugated anti-His tag mAb
(1:1000) in 1 × PBS (pH7.4) at 37°C for 2 h. Finally, the
membrane was washed with PBST three times and the
protein was identified by visualization with diaminoben-
zidine (DAB) as the substrate.
Purification of fusion protein
Identical volume of 100% saturated ammonium sulfate
(pH7.0) was slowly added to the 250 ml supernatant
obtained from the expression cultures, and the super-
natant was stored at 4°C overnight with constant stir-
ring, ensuring the proteins were thoroughly precipitated.
The proteins were harvested by centrifugation of
10000 g at 4°C for 30 min, resusupended in 20 ml1 × PBS,
and then dialyzed against 500 ml buffer of 20 mM
Tris–HCl (pH8.0), 150 mM NaCl at 4°C for 24 h,
changing the dialysis buffer once every 3 h to remove the
residual ammonium sulfate and impurities. The protein
was then purified by IMAC (immobilized-metal ion affin-
ity chromatography). Briefly, the protein solution was
loaded onto a 10 ml Ni-NTA agarose column, which was
pre-equilibrated with 10-fold volume of above dialysis buf-
fer at a flow rate of 0.5 ml/min. After loading of the mix-
ture, the column was washed with a buffer of 20 mM
Tris–HCl (pH8.0), 500 mM NaCl, 20 mM imidazole, at
1 ml/min until the absorbance reached the baseline. The
target protein was then eluted with a buffer of 20 mM
Tris–HCl (pH8.0), 150 mM NaCl, 500 mM imidazole at
1 ml/min, and was checked for its purity by 12% SDS/
PAGE. The eluted protein solution was re-dialyzed against
100-fold volume of 1 ×PBS buffer at 4°C overnight to re-
move the residual impurities, followed by centrifugation at
14000 g at 4°C for 30 min and passed through a 0.45 μm-
pore-size filter to remove the potential aggregations and
microorganisms. At last, the protein was concentrated
by ultracentrifugation using centriconmicro-concentrators
(Amersham Biosciences, UK), quantified by Bradford
method with BSA as control and lyophilized for use.
Analytical gel filtration
Analytical gel filtration of the fusion protein was per-
formed on an Amersham Pharmacia Biotech HPLC sys-
tem using a TSK-G3000-SWXL column (7.8 mm
diameter × 300 mm long; Tosoh Bioscience, Tokyo,
Japan) equilibrated with degassed PBS. Portion (20 μl) of
the fusion protein were injected at a concentration of
200 μg/ml. For calibration of the TSK-G3000-SWXL col-
umn, the standard proteins IgG (molecular mass
150 kDa) and BSA (66 kDa) were used. The molecular
mass of the fusion protein was determined according to
its retention time.
Receptor binding
Human melanoma A375.S2 cells were fixed with 4% par-
aformaldehyde and incubated with the fusion protein,
IL-1ra, or HSA at 25°C for 2 h. After three times wash-
ing with 1 × PBS, a FITC-labeled anti-His tag monoclo-
nal antibody (mAb) was added at a 1:500 dilution. The
cells were again washed three times with 1 ×PBS. Con-
focal microscopy was performed on an Olympus BX 50
WI microscope (Olympus, Melville, NY) coupled with a
TI:Sapphire laser (Spectraphysics, Irvine, CA) and a Ra-
diance 2000MP scanning confocal multiphoton imaging
system (BioRad Laboratories, Hercules, CA). Images
were taken at room temperature. Adobe Photoshop7.0
Software (Adobe, San Jose, CA) was used for subsequent
image processing.
Inhibition of IL-1β action
A375.S2 cell cultures were harvested in EDTA, washed,
and resuspended to 2.5 × 105 cells/ml in RPMI-1640
medium containing 10% FBS (foetal bovine serum,
Hyclone). 100 μl/well of cell suspension was added to a
96-well assay plate and incubated overnight at 37°C, 5%
CO2 in a humidified incubator. 100 μl/well of assay
medium (RPMI-1640 medium containing 2% FBS) was
added to another plate, and IL-1ra or fusion protein was
serially diluted in the 100 μl assay medium by 2-fold
from row 3 to row 12 in triplicate, followed by addition
of 100 μl/well of rhIL-1β to1 ng/ml (final concentration)
from row 2 to row 12. Row 1 was supplemented with
100 μl assay medium to an identical volume. 100 μl of
this mixed solution was then transferred to the corre-
sponding wells of the assay plate with cell culture. The
plate was incubated for 72 h at 37°C, 5% CO2 in a hu-
midified incubator. After incubation, 10 μl/well of 5 mg/
ml MTT solution was added and the plate was incubated
at 37°C, 5% CO2 for 4 h. The assay medium was dec-
anted and to each well 50 μl of MTT lysing solution was
added. A570 was then read and percentage inhibition was
calculated with the following formula: Inhibition (%) =
[[A570, M - A570, I]/[A570, N - A570, I]] × 100%. Where
A570, I is the mean value of absorbance of wells with
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addition of only rhIL-1β; A570, M is the mean value of
absorbance of wells with addition of the mixture solu-
tion of rhIL-1β and IL-1ra or fusion protein; and A570, N
is the absorbance of wells without addition of both rhIL-
1β and IL-1ra or fusion protein. HSA was used as a con-
trol protein in this assay.
Animal and arthritis model
Male DAB/1 mice, 7–8 weeks of age were obtained from
Chinese Academy of Medical Science (Beijing, China).
The animals were fed with standard rodent chows and
water, and the health status was monitored everyday. All
animal experiments were designed and conducted
according to the recommendations of Guidelines for Ex-
perimental Animal Administration approved by Institu-
tional Animal Care and Use Committee at the Hubei
Experimental Animal Regulation Board (Ezhengfa/1993/
79). Collagen-induced arthritis (CIA) was induced in
DAB/1 mice as described previously, by multiple intra-
dermal injections at the base of the tail and into three or
five other sites on the back, of 250 μg of bovine CII
(type II collagen) in 125 μl of 0.1 M acetic acid emulsi-
fied in an equal volume of Complete Freund’s adjuvant
containing 2 mg dry weight of Mycobacterium tubercu-
losis/ml. Mice were challenged again with the same dose
of preparation three weeks later by an intraperitoneal in-
jection. Disease developed about 11 days after the sec-
ond immunization. The arthritis model in mice
characterized by erythema and swelling of the paws in
one or more limbs.
Albumin measurement
5 mice with CIA and 5 healthy mice were sacrificed at
the time when the arthritis score arrived at a mean value
of above 10 per mouse. The blood samples were drawn
and serum albumin was analyzed using a commercial
quantitative ELISA kit according to the manufacturer’s
instruction. Data were expressed as g albumin/L serum.
Albumin levels in the paws of these mice were measured
by quantification of albumin in the joint extractions
using a commercial quantitative ELISA kit. Joint extrac-
tions were prepared in the same way as that used for
joint cytokines measurement described below. Data were
expressed as mg albumin/g tissue.
Pharmacokinetics and distribution of fusion protein
To qualify the circulation times and distribution of fu-
sion protein in health and inflamed joints, as well as in
the liver, kidney, spleen, and lung at different time
points, 55 mice with CIA and 55 healthy control mice
were randomly divided into eight groups, and received
an intravenous injection of 7.4 MBq of the radiolabeled
fusion protein IL-1ra-HSA (131I-IL-1ra-HSA), dissolved
in 50 μl PBS (pH7.4). Five mice with CIA and five
healthy mice were sacrificed at the time points of
10 min, 30 min, 1, 3, 8, 13, 24, 48, 72, 96, and 120 h after
tracer injection. All paws, livers, spleens, lungs and kid-
neys were prepared and weighed, and blood samples
were drawn. Radioactivity of blood and other tissues
were measured using a gamma-scintillation counter
(Berthold, Wildbad, Germany). The uptakes of the fu-
sion protein by the paws and other tissues were calcu-
lated as a percentage of the initially injected radioactivity
and the half-life in circulation was obtained from the
analysis of the plot of percentage of radioactivity in the
blood samples over time with a one-phasic exponential
function (GraphPad software). The paws of mice sacri-
ficed after 48 h were detected for the selective accumula-
tion of the radiolabeled fusion protein in inflamed and
normal joints by autoradiography using a phosphorima-
ger screen (Fujifilm, Dielsdorf, Switzerland).
To compare the pharmacokinetics of the fusion pro-
tein with that of IL-1ra, 7.4 MBq of radiolabeled IL-1ra
(131I- IL-1ra), dissolved in 50 μl PBS (pH7.4), was intra-
venously injected into 40 mice with CIA and 40 health
control mice, randomly divided into eight groups. At the
time points of 10 min, 30 min, 1, 3, 8, 13, 24, and 48 h,
five mice with CIA and five health mice were sacrificed
and all paws, livers, lungs, spleens, kidneys and blood
samples were prepared. The uptakes of IL-1ra by paws
and other organs, and the half-life in circulation were
calculated as mentioned above.
Treatment of mice CIA with fusion protein
On the 11th day after the second immunization, mice
were subdivided into five groups and receive the treat-
ment as follows: (1) normal control (n = 5); (2); CIA plus
saline (n = 5); (3) CIA plus HSA (n = 5); (4) CIA plus
IL-1ra (n = 5); (5) CIA plus fusion protein (n = 5). HSA,
IL-1ra, and fusion protein were each dissolved in physio-
logical saline (0.9% NaCl) to a concentration of 1 mg/ml,
and administered every other day by intraperitoneal in-
jection of 10 mg/kg body weight. The CIA control mice
receive intraperitoneal injection of physiological saline,
coinciding with the injection time of other groups. The
treatment continued for three weeks.
Arthritis assessment
The severity of the arthritis was monitored at 2-day
intervals using two disease indices (clinical score and
paw swelling). The clinical score for each limb was
graded from 0 to 4 as follows: 0 = normal; 1 = erythema;
2 = erythema plus slight swelling; 3 = pronounced
edematous swelling; 4 = joint rigidity or deformation.
Each limb was graded, giving a maximal score of 16 per
mouse. Clinical severity was also assessed by paw swel-
ling, obtained by measuring the thickness of each paw
with a dial-gauge caliper. The result was expressed as
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percentage increment in paw thickness relative to the
paw thickness before the onset of arthritis.
Histological analysis
Mice were killed at the end of the 21 days of therapy by
diethyl ether narcosis; hind limbs of each animal from
different experimental groups were removed and fixed in
10% formalin buffer. The limbs were decalcified in 5%
(v/v) nitric acid, processed for paraffin embedding, sec-
tioned at 5 μm thickness for the ankle joints, and subse-
quently stained with haematoxylin and eosin for
examination under an optical microscope. All ankle
joints were scored in a blind fashion for synovitis, bone
erosions, cartilage damage and fibrous inflammatory
hyperplasia using a predefined scoring system [43].
Briefly, the severity of each kind of the four pathological
changes was assessed using a semi-quantification
method and classified as normal, mild, moderate or se-
vere on the basis of the following criteria: 0 = normal,
no change; 1 = mild, minimal pathological change lim-
ited to discrete foci; 2 = moderate, pathological change
present but normal joint architecture intact; 3 = severe,
severe pathological change and joint architecture dis-
rupted. The histological score for each pathological
change was calculated by multiplying its score by its
weight (synovitis, bone erosions, and cartilage damage,
×1; fibrous inflammatory hyperplasia, ×3), on the basis
of the change’s importance in the pathology of mice
CIA. The total histological score for each joint was
obtained by addition of the histological score given for
each of the four pathological changes, giving a maximal
value 18 for a joint.
Joints cytokines measurement
Excised ankle and paw joints (including synovium, adja-
cent tissues and bones) of individual mouse from each
experiment group were immediately frozen in liquid ni-
trogen and pulverized using a mortar and pester. Tissue
was transferred to 15 ml tubes, placed on ice and resus-
pended in 1 ml 1 × PBS/200 mg of tissue (containing
protease inhibitor Phenylmethanesulfonyl fluoride) and
homogenized using a Biospec Tissue-Tearor (Biospec
Inc, USA) for 30 s. The homogenates were centrifuged
at 1000 g for 15 min at 4°C. Supernatants were trans-
ferred to 1.5 ml eppendorf tubes, centrifuged at 15000 g
for 10 min and collected for cytokines analysis using the
commercial quantitative ELISA kits for mouse TNF-α,
IL-1β, and IL-6 according to the manufacturer’s instruc-
tion. Data were expressed as pg cytokine/g tissue.
Statistical analysis
Data were expressed as mean ± SEM. The difference be-
tween the means of two groups were determined with Stu-
dent’s t test and was considered significant at p < 0.05.
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